FR13C0028I1 - CHIMERIC MODIFIED POLYPEPTIDES WITH ENHANCED PHARMACOKINETICS - Google Patents
CHIMERIC MODIFIED POLYPEPTIDES WITH ENHANCED PHARMACOKINETICSInfo
- Publication number
- FR13C0028I1 FR13C0028I1 FR13C0028C FR13C0028I1 FR 13C0028 I1 FR13C0028 I1 FR 13C0028I1 FR 13C0028 C FR13C0028 C FR 13C0028C FR 13C0028 I1 FR13C0028 I1 FR 13C0028I1
- Authority
- FR
- France
- Prior art keywords
- modified polypeptides
- enhanced pharmacokinetics
- chimeric modified
- pharmacokinetics
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Modified chimeric polypeptides with improved pharmacokinetics are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13813399P | 1999-06-08 | 1999-06-08 | |
EP00932721A EP1183353B1 (en) | 1999-06-08 | 2000-05-23 | Modified chimeric polypeptides with improved pharmacokinetic properties |
Publications (2)
Publication Number | Publication Date |
---|---|
FR13C0028I1 true FR13C0028I1 (en) | 2013-06-14 |
FR13C0028I2 FR13C0028I2 (en) | 2014-05-16 |
Family
ID=22480568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR13C0028C Active FR13C0028I2 (en) | 1999-06-08 | 2013-05-14 | CHIMERIC MODIFIED POLYPEPTIDES WITH ENHANCED PHARMACOKINETICS |
Country Status (33)
Country | Link |
---|---|
EP (2) | EP1544299B1 (en) |
JP (2) | JP4723140B2 (en) |
KR (1) | KR100659477B1 (en) |
CN (3) | CN101433715B (en) |
AT (2) | ATE417928T1 (en) |
AU (2) | AU779303B2 (en) |
BE (1) | BE2013C029I2 (en) |
BR (2) | BRPI0011407B8 (en) |
CA (1) | CA2376379C (en) |
CY (2) | CY1108883T1 (en) |
CZ (2) | CZ303656B6 (en) |
DE (2) | DE60041159D1 (en) |
DK (2) | DK1183353T3 (en) |
ES (2) | ES2237429T3 (en) |
FR (1) | FR13C0028I2 (en) |
HK (3) | HK1043388A1 (en) |
HR (1) | HRP20010908B1 (en) |
HU (3) | HU229156B1 (en) |
IL (3) | IL146890A0 (en) |
LT (1) | LTC1183353I2 (en) |
LU (1) | LU92195I2 (en) |
ME (2) | ME00024B (en) |
MX (1) | MXPA01012630A (en) |
NO (3) | NO330775B1 (en) |
NZ (1) | NZ515913A (en) |
PL (1) | PL208247B1 (en) |
PT (2) | PT1544299E (en) |
RS (1) | RS50073B (en) |
RU (1) | RU2265661C2 (en) |
SK (1) | SK287332B6 (en) |
UA (1) | UA74146C2 (en) |
WO (1) | WO2000075319A1 (en) |
ZA (1) | ZA200110068B (en) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6710174B2 (en) | 2001-09-13 | 2004-03-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of vascular endothelial growth factor receptor-1 expression |
EP1353952B1 (en) | 1994-11-14 | 2007-04-11 | Ludwig Institute For Cancer Research | Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US6734017B2 (en) | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
EP2301564A1 (en) | 2002-05-04 | 2011-03-30 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
SI1608685T1 (en) * | 2003-03-28 | 2007-08-31 | Regeneron Pharma | Vegf antagonists for the treatment of diabetes |
MX348062B (en) | 2003-05-16 | 2017-05-26 | Acorda Therapeutics Inc | Proteoglycan degrading mutants for treatment of cns. |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
WO2004110359A2 (en) * | 2003-05-16 | 2004-12-23 | Acorda Therapeutics, Inc. | Fusion proteins for the treatment of cns |
WO2004106378A2 (en) * | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using vegf antagonists |
US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
AR046510A1 (en) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT |
JP2007501239A (en) * | 2003-08-06 | 2007-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Use of VEGF antagonists in combination with radiation therapy |
ES2411504T3 (en) | 2004-05-18 | 2013-07-05 | Acorda Therapeutics, Inc. | Chondroitinase purification methods and stable formulations thereof |
RU2355414C2 (en) * | 2004-06-08 | 2009-05-20 | Чэнгду Кангхонг Байотекнолоджиз Ко., Лтд. | Chimeric proteins, inhibiting angiogenesis, and their application |
US7354580B2 (en) | 2004-06-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of human cancer |
CA2568534A1 (en) * | 2004-06-18 | 2006-01-26 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
US7378095B2 (en) | 2004-07-30 | 2008-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
PL2229956T3 (en) * | 2004-09-13 | 2013-09-30 | Genzyme Corp | Multimeric constructs |
FR2878749B1 (en) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | ANTITUMOR COMBINATIONS CONTAINING IN VEGT INHIBITOR AGENT AND 5FU OR ONE OF ITS DERIVATIVES |
CA2621047A1 (en) * | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
HUE034109T2 (en) | 2005-03-25 | 2018-01-29 | Regeneron Pharma | Vegf antagonist formulations |
ES2393748T3 (en) | 2005-09-26 | 2012-12-27 | Acorda Therapeutics, Inc. | Compositions and methods of using ABCI chondroitinase mutants |
EP1962895B2 (en) † | 2005-12-16 | 2016-01-20 | Regeneron Pharmaceuticals, Inc. | THERAPEUTIC USE OF A Dll4 ANTAGONIST AND A VEGF INHIBITOR FOR INHIBITING TUMOR GROWTH |
FR2895258B1 (en) | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS |
CN100502945C (en) * | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Application of fusion protein of VEGF receptor for treating disease of eye |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
US7608261B2 (en) | 2006-06-16 | 2009-10-27 | Regeneron Pharmacuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
MX2009003229A (en) | 2006-09-29 | 2009-06-18 | Oncomed Pharm Inc | Compositions and methods for diagnosing and treating cancer. |
WO2008045970A2 (en) | 2006-10-10 | 2008-04-17 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
FR2918279B1 (en) * | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | ANTITUMOR COMBINATIONS CONTAINING A VEGF INHIBITOR AGENT AND IRINOTECAN |
CN101575379B (en) * | 2008-05-09 | 2012-05-30 | 上海抗体药物国家工程研究中心有限公司 | Soluble VEGFR difunctional fusion receptors, preparation method and use thereof |
DK2358746T3 (en) | 2008-11-03 | 2020-12-21 | Molecular Partners Ag | BINDING PROTEINS TO INHIBIT THE VEGF-A RECEPTOR INTERACTION |
CN101838329A (en) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | Anti-angiogenesis fusion protein |
US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
TWI510246B (en) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | Modified binding proteins inhibiting the vegf-a receptor interaction |
SI2601214T1 (en) | 2010-08-06 | 2018-03-30 | Genzyme Corporation | Vegf antagonist compositions and uses thereof |
JP6043629B2 (en) * | 2011-01-07 | 2016-12-14 | 中外製薬株式会社 | Methods for improving antibody physical properties |
MX349901B (en) | 2011-01-13 | 2017-08-18 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders. |
JO3283B1 (en) | 2011-04-26 | 2018-09-16 | Sanofi Sa | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
KR101397088B1 (en) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | A fusion protein for inhibiting both angiogenesis and tumor cell proliferation, and composition comprising the same |
JO3370B1 (en) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | Methods of inhibiting tumor growth by antagonizing il-6 receptor |
JP6138815B2 (en) * | 2011-12-01 | 2017-05-31 | エーピー バイオサイエンシーズ, インコーポレイテッド | Protein inhibitors for the complement and VEGF pathways and methods for their use |
CN103304668B (en) * | 2012-03-12 | 2015-10-28 | 江苏健德生物药业有限公司 | Ultra-VEGF-trap immune fusion protein, its preparation method and application thereof |
ES2753135T3 (en) | 2012-05-07 | 2020-04-07 | Allergan Inc | Treatment method of AMD in patients resistant to anti-VEGF therapy |
WO2014006113A1 (en) | 2012-07-03 | 2014-01-09 | Sanofi | Method of treating cancer by effective amounts of aflibercept |
TW201438736A (en) | 2012-11-14 | 2014-10-16 | Regeneron Pharma | Methods of treating ovarian cancer with Dll4 antagonists |
NZ710658A (en) | 2013-02-18 | 2019-12-20 | Vegenics Pty Ltd | Ligand binding molecules and uses thereof |
AR095196A1 (en) * | 2013-03-15 | 2015-09-30 | Regeneron Pharma | SERUM FREE CELL CULTIVATION MEDIA |
CN104193828B (en) * | 2013-09-12 | 2017-04-05 | 北京韩美药品有限公司 | The recombination fusion protein of HER2 and VEGFR signal paths is blocked simultaneously |
EP3065761B1 (en) | 2013-11-05 | 2020-01-08 | Allergan, Inc. | Method of treating conditions of the eye with an anti-vegf darpin |
JP6802069B2 (en) | 2014-05-12 | 2020-12-16 | フォーマイコン アーゲーFormycon Ag | Prefilled plastic syringe containing VEGF antagonist |
DK3170005T3 (en) | 2014-07-18 | 2019-07-08 | Sanofi Sa | PROCEDURE FOR THE PREPARATION OF THE RESULTS OF A TREATMENT WITH A DELIVERY AT A PATIENT THAT IS DISPUTED TO CANCER |
JP2016036322A (en) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | Chimeric protein binding to angiogenic factor |
CN114306575A (en) | 2014-12-11 | 2022-04-12 | 拜耳医药保健有限责任公司 | Treatment of age-related macular degeneration with small active choroidal neovascularisation |
GB201503453D0 (en) | 2015-03-01 | 2015-04-15 | Jain Arjun | Endothelin-1"sponge" |
TW202330904A (en) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
WO2017046140A1 (en) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
WO2017065559A1 (en) | 2015-10-15 | 2017-04-20 | (주)알테오젠 | Method for producing fusion protein having igg fc domain |
KR101936049B1 (en) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | Method for manufacturing fusion proteins with IgG Fc domain |
KR102354198B1 (en) | 2015-11-18 | 2022-01-20 | 에스아이오2 메디컬 프로덕츠, 인크. | Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist |
JP7430485B2 (en) | 2015-11-18 | 2024-02-13 | エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド | Pharmaceutical packaging for ophthalmic preparations |
EP3377151A1 (en) | 2015-11-18 | 2018-09-26 | Formycon AG | Pre-filled plastic syringe containing a vegf antagonist |
WO2017084616A1 (en) * | 2015-11-19 | 2017-05-26 | Zhuhai Tairuishang Biopharm Ltd. | Methods and compositions for binding vegf |
EP3384049B1 (en) | 2015-12-03 | 2023-08-02 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
EP3407868A1 (en) | 2016-01-26 | 2018-12-05 | Formycon AG | Liquid formulation of a vegf antagonist |
WO2018070390A1 (en) | 2016-10-12 | 2018-04-19 | 第一三共株式会社 | Composition containing anti-robo4 antibody and other agents |
CA3043487A1 (en) | 2016-11-21 | 2018-05-24 | Just Biotherapeutics, Inc. | Aflibercept formulations and uses thereof |
US20200237997A1 (en) | 2017-05-24 | 2020-07-30 | Formycon Ag | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
CA3063995A1 (en) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
TW201904610A (en) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | Non-antibody vegf antagonists for the treatment of neovascular glaucoma |
WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | Liquid formulation of a vegf antagonist |
WO2019036626A1 (en) | 2017-08-17 | 2019-02-21 | Just Biotherapeutics, Inc. | Method of purifying glycosylated protein from host cell galectins and other contaminants |
CA3081094A1 (en) | 2017-11-20 | 2019-05-23 | Alison J. GILLESPIE | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
EP4219695A3 (en) | 2017-11-27 | 2024-01-17 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
RS63703B1 (en) | 2017-11-30 | 2022-11-30 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
CN117405806A (en) * | 2017-12-13 | 2024-01-16 | 里珍纳龙药品有限公司 | Apparatus, system and associated method for managing chromatography bed support |
KR20200112893A (en) * | 2018-01-26 | 2020-10-05 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Methods and compositions for treating angiogenic disorders using anti-VEGF agents |
MX2020011848A (en) | 2018-05-10 | 2021-03-29 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations. |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
CN111378044B (en) | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | Antibody fusion protein, preparation method and application thereof |
US20220204920A1 (en) | 2019-05-16 | 2022-06-30 | Formycon Ag | Method for reducing methionine oxidation in recombinant proteins |
WO2021046070A1 (en) | 2019-09-03 | 2021-03-11 | Amgen Inc. | Injection device for drug delivery and packaging for the injection device |
EP4031208A1 (en) | 2019-09-16 | 2022-07-27 | Amgen Inc. | Method for external sterilization of drug delivery device |
AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
BR112022010113A2 (en) | 2019-11-25 | 2022-09-06 | Univ California | LONG-ACTING VEGF INHIBITORS FOR INTRAOCULAR NEOVASCULARIZATION |
JP2023505216A (en) | 2019-12-06 | 2023-02-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | VEGF mini-traps and methods of their use |
NZ781142A (en) | 2019-12-06 | 2023-05-26 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
AU2021226754A1 (en) | 2020-02-24 | 2022-07-07 | Amgen Inc. | Containers and systems for use during external sterilization of drug delivery devices |
EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
KR20240019034A (en) * | 2022-08-02 | 2024-02-14 | 주식회사 파노로스바이오사이언스 | Modified fusion protein and the use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
-
2000
- 2000-05-23 KR KR1020017015839A patent/KR100659477B1/en active Protection Beyond IP Right Term
- 2000-05-23 EP EP05001328A patent/EP1544299B1/en not_active Expired - Lifetime
- 2000-05-23 ES ES00932721T patent/ES2237429T3/en not_active Expired - Lifetime
- 2000-05-23 RU RU2002100071/13A patent/RU2265661C2/en active Protection Beyond IP Right Term
- 2000-05-23 PT PT05001328T patent/PT1544299E/en unknown
- 2000-05-23 JP JP2001502582A patent/JP4723140B2/en not_active Expired - Lifetime
- 2000-05-23 AU AU50404/00A patent/AU779303B2/en active Active
- 2000-05-23 BR BRPI0011407A patent/BRPI0011407B8/en unknown
- 2000-05-23 HU HU0201515A patent/HU229156B1/en active Protection Beyond IP Right Term
- 2000-05-23 BR BR0011407-3A patent/BR0011407A/en not_active IP Right Cessation
- 2000-05-23 MX MXPA01012630A patent/MXPA01012630A/en active IP Right Grant
- 2000-05-23 PT PT00932721T patent/PT1183353E/en unknown
- 2000-05-23 SK SK1752-2001A patent/SK287332B6/en not_active IP Right Cessation
- 2000-05-23 ME MEP-2008-32A patent/ME00024B/en unknown
- 2000-05-23 CN CN2008101093559A patent/CN101433715B/en not_active Expired - Lifetime
- 2000-05-23 CA CA002376379A patent/CA2376379C/en not_active Expired - Lifetime
- 2000-05-23 IL IL14689000A patent/IL146890A0/en unknown
- 2000-05-23 AT AT05001328T patent/ATE417928T1/en active
- 2000-05-23 ME MEP-32/08A patent/MEP3208A/en unknown
- 2000-05-23 CZ CZ20100386A patent/CZ303656B6/en not_active IP Right Cessation
- 2000-05-23 NZ NZ515913A patent/NZ515913A/en not_active IP Right Cessation
- 2000-05-23 DE DE60041159T patent/DE60041159D1/en not_active Expired - Lifetime
- 2000-05-23 CN CNB008115443A patent/CN100523187C/en not_active Expired - Lifetime
- 2000-05-23 EP EP00932721A patent/EP1183353B1/en not_active Expired - Lifetime
- 2000-05-23 RS YUP-869/01A patent/RS50073B/en unknown
- 2000-05-23 UA UA2001128378A patent/UA74146C2/en unknown
- 2000-05-23 CZ CZ20014387A patent/CZ302689B6/en unknown
- 2000-05-23 DK DK00932721T patent/DK1183353T3/en active
- 2000-05-23 DK DK05001328T patent/DK1544299T3/en active
- 2000-05-23 DE DE60019415T patent/DE60019415T2/en not_active Expired - Lifetime
- 2000-05-23 PL PL352246A patent/PL208247B1/en active Protection Beyond IP Right Term
- 2000-05-23 AT AT00932721T patent/ATE293164T1/en active
- 2000-05-23 ES ES05001328T patent/ES2319305T3/en not_active Expired - Lifetime
- 2000-05-23 HU HU1300086A patent/HU230159B1/en unknown
- 2000-05-23 CN CN201310118971.1A patent/CN103349781B/en not_active Expired - Lifetime
- 2000-05-23 WO PCT/US2000/014142 patent/WO2000075319A1/en active Application Filing
-
2001
- 2001-12-03 IL IL146890A patent/IL146890A/en active Protection Beyond IP Right Term
- 2001-12-06 ZA ZA200110068A patent/ZA200110068B/en unknown
- 2001-12-07 HR HR20010908A patent/HRP20010908B1/en not_active IP Right Cessation
- 2001-12-10 NO NO20016036A patent/NO330775B1/en active Protection Beyond IP Right Term
-
2002
- 2002-07-04 HK HK02105009A patent/HK1043388A1/en not_active IP Right Cessation
-
2005
- 2005-03-31 AU AU2005201365A patent/AU2005201365B2/en not_active Expired
-
2008
- 2008-03-17 IL IL190234A patent/IL190234A0/en not_active IP Right Cessation
-
2009
- 2009-03-16 CY CY20091100288T patent/CY1108883T1/en unknown
- 2009-11-05 HK HK09110323.8A patent/HK1132653A1/en unknown
-
2010
- 2010-05-06 NO NO20100656A patent/NO332559B1/en not_active IP Right Cessation
- 2010-10-06 JP JP2010226970A patent/JP5273746B2/en not_active Expired - Lifetime
-
2013
- 2013-05-13 CY CY2013019C patent/CY2013019I1/en unknown
- 2013-05-13 BE BE2013C029C patent/BE2013C029I2/fr unknown
- 2013-05-14 LT LTPA2013009C patent/LTC1183353I2/en unknown
- 2013-05-14 LU LU92195C patent/LU92195I2/en unknown
- 2013-05-14 FR FR13C0028C patent/FR13C0028I2/en active Active
- 2013-05-15 NO NO2013010C patent/NO2013010I1/en unknown
- 2013-09-17 HU HUS1300052C patent/HUS1300052I1/en unknown
- 2013-11-26 HK HK13113191.5A patent/HK1185798A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR13C0028I2 (en) | CHIMERIC MODIFIED POLYPEPTIDES WITH ENHANCED PHARMACOKINETICS | |
ATE396738T1 (en) | USE OF GLP-2 PEPTIDES | |
DE60136272D1 (en) | DIAGNOSTICS AND THERAPEUTICS FOR MACULAR DEGENERATION DISEASES | |
BR0309549B1 (en) | "smoking article, and method for controlling the static burning rate of a smoking article". | |
HU229108B1 (en) | Glucagon-like peptide-1 analogs | |
DE60118921D1 (en) | Methods and compositions using quinazolinones | |
NO20012160L (en) | Device for treating macular degeneration | |
DE602006016760D1 (en) | COMPOSITIONS AND METHODS FOR CONTROLLING, PREVENTING AND TREATING FOODSTUFFS | |
ATE397458T1 (en) | NEW CURE FOR CANCER | |
AU4128901A (en) | Colored visco-elastic composition | |
WO2006091666A3 (en) | Methods and compositions for treating conditions of the eye | |
DE60008151D1 (en) | 5-HT2 AGONISTS AS A MEANS FOR CONTROLLING THE EYE PRESSURE AND FOR TREATING GLAUCOMA | |
TR199501276A2 (en) | Substituted cycloalkylamino-and-alkoxy-heterocycyls are used as methods and pest control agents for their production. | |
RU95118972A (en) | METHOD FOR TREATING ATHEROSCLEROTIC MACULODYSTROPHIES BY DIRECT LASEROPHARESIS METHOD | |
Mulvihill | Love's Labors Found——Deep in the Brain | |
RU2000100655A (en) | METHOD FOR SURGICAL CORRECTION OF PRESBIOPIA |